Lyra Therapeutics Inc at Jefferies Healthcare Conference Transcript
Hi, good morning, and welcome to the 2023 Jefferies Healthcare Conference. My name is Dennis Ding, biotech analyst here at Jefferies. I've the wonderful pleasure of having Lyra Therapeutics here, and CEO, Maria Palasis. Thanks for joining us.
Thank you, Dennis. It's great to be here.
So before we dive into some of the questions, maybe give us a background around the company, some of the progress you have made over the last 12 to 24 months, and the outlook ahead.
So our company is Lyra Therapeutics, and we are focused on developing treatments for chronic rhinosinusitis. Chronic rhinosinusitis or CRS, as we call it, is -- it's a really big problem, not just in the US but throughout the world. Sometimes people refer to it as an
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
